Cargando…
CD86 Molecule Might Be a Novel Immune-Related Prognostic Biomarker for Patients With Bladder Cancer by Bioinformatics and Experimental Assays
As one of the most common malignancies in the urinary system, bladder cancer (BC) occupies a high mortality and recurrence rate. BC carries an ominous prognosis. Thus, we aimed to identify a novel immune-related prognostic biomarker and therapeutic target for immunotherapy in the present study. We f...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8378807/ https://www.ncbi.nlm.nih.gov/pubmed/34422632 http://dx.doi.org/10.3389/fonc.2021.679851 |
_version_ | 1783740883837911040 |
---|---|
author | Yan, Xin Du, Guo-Wei Chen, Zhao Liu, Tong-Zu Li, Sheng |
author_facet | Yan, Xin Du, Guo-Wei Chen, Zhao Liu, Tong-Zu Li, Sheng |
author_sort | Yan, Xin |
collection | PubMed |
description | As one of the most common malignancies in the urinary system, bladder cancer (BC) occupies a high mortality and recurrence rate. BC carries an ominous prognosis. Thus, we aimed to identify a novel immune-related prognostic biomarker and therapeutic target for immunotherapy in the present study. We first constructed a co-expression network based on immune-related genes (IRGs). Two key modules showed high association with the clinical feature interested us most were further identified. Forty-five IRGs were screened out and regarded as hub genes in the co-expression network. We further constructed a protein-protein interaction (PPI) network, and five independent methods were used for hub gene identification. Three hub genes were identified in the present study. CD86 molecule (CD86) was screened out by performing overall survival (OS) analysis. Subsequent analyses by using some bioinformatics and experimental assays confirmed that CD86 was an immune-related prognostic biomarker, which might be a novel target for immunotherapy in BC. A small molecule drug named suloctidil was also identified, which showed potential for BC treatment. |
format | Online Article Text |
id | pubmed-8378807 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-83788072021-08-21 CD86 Molecule Might Be a Novel Immune-Related Prognostic Biomarker for Patients With Bladder Cancer by Bioinformatics and Experimental Assays Yan, Xin Du, Guo-Wei Chen, Zhao Liu, Tong-Zu Li, Sheng Front Oncol Oncology As one of the most common malignancies in the urinary system, bladder cancer (BC) occupies a high mortality and recurrence rate. BC carries an ominous prognosis. Thus, we aimed to identify a novel immune-related prognostic biomarker and therapeutic target for immunotherapy in the present study. We first constructed a co-expression network based on immune-related genes (IRGs). Two key modules showed high association with the clinical feature interested us most were further identified. Forty-five IRGs were screened out and regarded as hub genes in the co-expression network. We further constructed a protein-protein interaction (PPI) network, and five independent methods were used for hub gene identification. Three hub genes were identified in the present study. CD86 molecule (CD86) was screened out by performing overall survival (OS) analysis. Subsequent analyses by using some bioinformatics and experimental assays confirmed that CD86 was an immune-related prognostic biomarker, which might be a novel target for immunotherapy in BC. A small molecule drug named suloctidil was also identified, which showed potential for BC treatment. Frontiers Media S.A. 2021-08-06 /pmc/articles/PMC8378807/ /pubmed/34422632 http://dx.doi.org/10.3389/fonc.2021.679851 Text en Copyright © 2021 Yan, Du, Chen, Liu and Li https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Yan, Xin Du, Guo-Wei Chen, Zhao Liu, Tong-Zu Li, Sheng CD86 Molecule Might Be a Novel Immune-Related Prognostic Biomarker for Patients With Bladder Cancer by Bioinformatics and Experimental Assays |
title | CD86 Molecule Might Be a Novel Immune-Related Prognostic Biomarker for Patients With Bladder Cancer by Bioinformatics and Experimental Assays |
title_full | CD86 Molecule Might Be a Novel Immune-Related Prognostic Biomarker for Patients With Bladder Cancer by Bioinformatics and Experimental Assays |
title_fullStr | CD86 Molecule Might Be a Novel Immune-Related Prognostic Biomarker for Patients With Bladder Cancer by Bioinformatics and Experimental Assays |
title_full_unstemmed | CD86 Molecule Might Be a Novel Immune-Related Prognostic Biomarker for Patients With Bladder Cancer by Bioinformatics and Experimental Assays |
title_short | CD86 Molecule Might Be a Novel Immune-Related Prognostic Biomarker for Patients With Bladder Cancer by Bioinformatics and Experimental Assays |
title_sort | cd86 molecule might be a novel immune-related prognostic biomarker for patients with bladder cancer by bioinformatics and experimental assays |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8378807/ https://www.ncbi.nlm.nih.gov/pubmed/34422632 http://dx.doi.org/10.3389/fonc.2021.679851 |
work_keys_str_mv | AT yanxin cd86moleculemightbeanovelimmunerelatedprognosticbiomarkerforpatientswithbladdercancerbybioinformaticsandexperimentalassays AT duguowei cd86moleculemightbeanovelimmunerelatedprognosticbiomarkerforpatientswithbladdercancerbybioinformaticsandexperimentalassays AT chenzhao cd86moleculemightbeanovelimmunerelatedprognosticbiomarkerforpatientswithbladdercancerbybioinformaticsandexperimentalassays AT liutongzu cd86moleculemightbeanovelimmunerelatedprognosticbiomarkerforpatientswithbladdercancerbybioinformaticsandexperimentalassays AT lisheng cd86moleculemightbeanovelimmunerelatedprognosticbiomarkerforpatientswithbladdercancerbybioinformaticsandexperimentalassays |